Your browser doesn't support javascript.
loading
Reply: SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents.
Dai, Cong; Dong, Zi-Yuan; Wang, Yi-Nuo; Huang, Yu-Hong; Jiang, Min.
  • Dai C; gastroenterology, First Affiliated Hospital. China Medical University, china.
  • Dong ZY; Gastroenterology, First Affiliated Hospital. China Medical University.
  • Wang YN; Gastroenterology, First Affiliated Hospital. China Medical University.
  • Huang YH; Gastroenterology, First Affiliated Hospital. China Medical University.
  • Jiang M; Gastroenterology, First Affiliated Hospital. China Medical University.
Rev Esp Enferm Dig ; 115(10): 584, 2023 Oct.
Article en En | MEDLINE | ID: mdl-36633163
ABSTRACT
We thank Dr Mungmunpuntipantip and colleague for their interest and thoughtful comments on our publication. The authors have highlighted several important considerations for the impact of SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients with different biological agents. We fully agree with the author's point of view, and we also point out the limitations in our meta-analysis.
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2023 Tipo del documento: Article